ExpressPoints: The New Biomarkers Pathologists Need to Know for Precision Therapy in Lung Cancer

Download this short summary slideset of key takeaways from a live CCO Webinar featuring a medical oncologist and molecular pathologist discussing established and emerging biomarkers critical to optimal treatment of patients with advanced NSCLC.
Nathan Pennell, MD, PhD
Laura J. Tafe, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 638 KB
Released: November 24, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Downloadable CCO resource summarizing best practices for detection of RET gene alterations in lung and thyroid tumors

Released: January 21, 2021

Downloadable CCO resource summarizing efficacy data for recently FDA-approved next-generation RET inhibitors in lung and thyroid cancers

Released: January 21, 2021

Short downloadable CCO resource summarizing approved indications, dosing, and key safety data for the selective RET inhibitors pralsetinib and selpercatinib

Released: January 21, 2021

Download slides reviewing the latest clinical data informing optimal treatment of patients with RET-altered NSCLC and thyroid cancer, from Clinical Care Options

Taofeek K. Owonikoko, MD, PhD Released: January 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue